Anna Sitthi-Amorn

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and ...

Daratumumab-bortezomib-lenalidomide-dexamethason bij myeloom: PERSEUS fase III